Resources
34 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 3/29/2024
The Centers for Disease Control and Prevention (CDC) has naloxone trainings and fact sheets available for clinicians. The trainings and fact sheets can help clinicians raise awareness about the benefits of naloxone by talking with patients and their family, friends, and caregivers.
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
Posted 1/8/2024 (updated 3/28/2024)
The Neonatal Abstinence Syndrome (NAS) Cohort I tip sheet is a result of collaborative efforts of the NAS Cohort I grant recipients. Drawing on the insights and experiences of our grantees, we identified 9 key recommendations. These tips serve not only as a guiding framework for future NAS cohort grantees but also offers valuable guidance to all RCORP grant cohorts. This resource aims to enhance effectiveness and increase the impact of all RCORP grantee initiatives.
Posted 12/1/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention and the National Organization of State Offices of Rural Health have joined with two philanthropic organizations with experience in minority communities – Well-being and Equity (WE) in the World and Well Being In the Nation (WIN) Network – to collaborate on guidelines for what it will take to bring health equity to rural areas.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
RSV 2023 Session: Quick Response Teams: Preventing Deaths While Sharing the Hope of Recovery (Day 1)
Posted 7/26/2023 (updated 3/28/2024)
The presentation discussed the development and changes in the utilization of a Quick Response Team in an Ohio rural community.
Posted 7/26/2023 (updated 3/28/2024)
In this session, we described how we used RCORP-Planning and RCORP-Implementation funds to plan, establish, and grow integrated harm reduction and recovery services in one space, the Fayette County Connection Café. Certified peer recovery coaches facilitated and staff Connection Café services, including peer support mutual aid groups, syringe services programming, street outreach, harm reduction vending machine, and 24-hour access to Naloxone.
Posted 7/21/2023 (updated 3/28/2024)
Disparities in access to naloxone exist and organizations are working to remove some of these barriers by utilizing innovative methods such as vending machines to distribute the overdose medication. This provides life-saving medication in an accessible way to everyone, although laws vary state to state on the distribution of these tools. More information on naloxone vending machines can be found in these resources by the Bureau of Justice Assistance's (BJA) Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) and The Network for Public Health Law.
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.